

INDEX

- acinar carcinoma
 - pancreas, 147–8
- acinic cell carcinoma, 95, 103, 104, 106
- actinic keratoses, 32, 33, 38
- adenoid cystic carcinoma, 94
- adnexal neoplasms, 34
- alcian blue stain, 21
- alcian yellow stain, 21
- ampullary adenomas and adenocarcinomas, 121–2
- ampullary and periampullary lesions, 137–8
- aneurysmal bone cyst, 309–11
- appendiceal neoplasms
 - endocrine tumors, 125
 - low-grade mucinous neoplasms, 114–17
- atypical decubital fibroplasia, 293–4
- atypical fibroxanthoma, 38
- atypical teratoid rhabdoid tumor, 283
- Azzopardi phenomenon, 84, 85
- Barrett’s esophagus, 113, 120–1
- basal cell adenocarcinoma, 94
- basal cell adenoma, 94, 102
- basal cell carcinoma (BCC), 30–2
 - clinical issues, 30
 - infiltrative type, 30, 31
 - micronodular type, 30, 31
 - morphea type, 30, 31
 - nodular type, 30–1
 - pathologic issues, 30–2
 - superficial type, 30, 31
- basaloid squamous cell carcinoma
 - upper aerodigestive tract, 48
- Beckwith-Weidemann syndrome, 150
- bile duct adenoma, 133, 134
- bile duct hamartoma, 133
- biliary atresia, 333–5
- bone and joint lesions, 304–20
 - aneurysmal bone cyst, 309–11
 - approach to making a diagnosis, 304
 - approach to managing bone tumors, 305
 - cartilaginous tumors, 311–14
 - chondroblastoma, 309–11
 - CT-guided FNA and needle core biopsy, 305
 - diagnostic challenges, 304
 - diagnostic procedures, 305
 - enchondroma, 313–14
 - evaluation of surgical margins, 317–18
 - general pathologic issues, 307–9
 - giant cell rich lesions, 309–11
 - giant cell rich osteosarcoma, 309–11
 - giant cell tumor, 309–11
 - high-grade chondrosarcoma, 311–12
 - incisional biopsy, 305
 - indications for intraoperative consultation (IOC), 306
 - infection in reimplantation arthroplasties, 319–20
 - information needed before and during IOC, 306–7
 - low-grade chondrosarcoma, 313–14
 - management of primary malignancies, 304
 - osteogenic neoplasms, 314–17
 - osteomyelitis, 318–19
 - osteosarcoma, 314–17
 - purpose of intraoperative diagnosis, 304
 - small round cell neoplasms, 317
 - types of surgery, 305
- Bowen’s disease, 32
- breast, 192–206
 - changing management of breast cancer, 192
 - duct carcinoma in situ (DCIS), 192, 196, 199–3, 202–3
 - evaluating completeness of excision, 199
 - evaluation of mastectomy specimens, 201
 - evaluation of reduction mammoplasties, 201
 - excisional biopsy specimens, 193
 - excisional biopsy specimens for initial diagnosis, 193
 - histological distinctions in lumpectomy specimens, 199–200
 - indications for intraoperative consultation (IOC), 192
 - information needed before and during IOC, 192–3
 - J-wire biopsy for initial diagnosis, 193–4
 - lumpectomy specimen evaluation for carcinoma, 194–9
 - lumpectomy specimens, 13, 192–3
 - newer surgical approaches, 1
 - phyllodes tumors, 200–1
 - sentinel lymph node biopsy, 201–6
- Brenner tumor, 217
- Burkitt’s lymphoma, 262
- carcinosarcoma
 - upper aerodigestive tract, 49–50
- cartilaginous tumors, 311–14
- Castleman’s disease, 89
- cellular myofibroblastic lesions, 295
- cellular schwannoma, 294–5
- central nervous system, 265–87
 - approach to intraoperative diagnosis, 265
 - biopsies for medical diseases, 287
 - circumscribed gliomas and glioneural tumors, 276–7
 - complete surgical resection, 266
 - Creutzfeldt cells, 272
 - cytologic preparations, 268
 - demyelinating disorders, 272
 - distinguishing normal from abnormal tissue, 270–2
 - evaluation of margins, 284
 - frozen sections, 268
 - ganglioglioma, 276
 - general clinical issues, 265–6
 - glioblastoma, 273
 - gliomas, 272–3
 - gliosis, 272
 - granular mitoses, 272
 - gross examination of specimens, 267
 - heterogeneity of gliomas in stereotactic biopsies, 272–3
 - high-grade neoplasms in adults, 273
 - indications for intraoperative diagnosis, 266
 - infarcts, 272
 - inflammatory and reactive conditions, 272
 - information required before and during IOC, 266–7
 - lymphoma, 273
 - lymphoproliferative lesions, 281–2
 - macrophage-rich lesions, 272
 - managerial vs. scientific diagnoses, 265
 - meningiomas, 278–80
 - metastases, 273, 280–1
 - oligodendrogliomas, 274–5
 - pilocytic astrocytoma, 276
 - piloid gliosis, 272
 - pilomyxoid astrocytoma, 277
 - pineal neoplasms, 287
 - pleomorphic xanthoastrocytoma, 276
 - primary vs. metastatic neoplasm, 280–1
 - radiation treatment effects, 277–8
 - reactive and inflammatory conditions, 272
 - recurrent gliomas and treatment effect, 277–8
 - sellar lesions, 285–6
 - small round blue cell tumors, 283
 - specimen handling, 267–70
 - spinal cord lesions, 283–4
 - squash and smear preparations, 19
 - stereotactic needle biopsy, 266, 272–3
 - subacute gliosis, 272
 - subtotal resection, 266
 - surgical procedures relevant to IOD, 266
- central neuroectodermal tumors, 283

INDEX

- cervix
 - cervical carcinoma, 232–3
- cholangiocarcinoma of the proximal biliary tract, 137
- chondroblastoma, 309–11
- chondrosarcoma, 311–12, 313–14
- choriocarcinoma, 87
- chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 258
- clear cell eccrine carcinoma, 34
- clear cell neoplasms
 - salivary glands, 104–5
- clinico-pathologic correlation in IOD, 5–6
- colonic endocrine tumors, 125
- colorectal carcinoma, 117–18
- communication between pathologist and surgeon, 5–6, 8
- craniopharyngiomas, 286
- Crohn’s disease, 118–19
- cryostats, 15
- cutaneous malignancies, 24–39
 - actinic keratoses, 32, 38
 - adnexal neoplasms, 34
 - basal cell carcinoma (BCC), 30–2
 - Bowen’s disease, 32
 - capacity to metastasize, 24–5
 - cutting the specimen, 25
 - embedding the specimen, 27–8
 - extramammary Paget’s disease, 37
 - general clinical issues, 24–5
 - indications for intraoperative diagnosis, 24
 - information needed before and during IOD, 24
 - inking the specimen, 25
 - lymphomas, 262
 - melanocytic neoplasms, 36–7
 - melanoma, 36–7
 - Merkel cell carcinoma, 34–5
 - Mohs micrographic surgery, 28–9
 - non-sparing of tissue when evaluating surgical margins, 28
 - non-surgical treatments, 24
 - orientation of the specimen, 25
 - removing excess fat from a specimen, 27
 - sebaceous carcinoma, 33–4
 - squamous cell carcinoma (SCC), 32–3
 - types of skin specimen, 25
 - unrelated lesions on FS slides, 38
- cystadenoma, 102
- cystic metastatic SCC in cervical lymph nodes, 55
- cystic neoplasms of the pancreas, 151–8
- cytologic examination of specimens, 18–19
 - cytologic preparation techniques, 18–19
 - limitations of cytologic preparations, 18
 - when cytologic preparations should be used, 18
- cytologic preparation techniques, 18–19
 - avoidance of contamination, 19
 - cytoscraps preparations, 19
 - scrape and smear preparations, 19
 - squash and smear preparations, 19
 - touch imprints or touch preparations, 18
- cytoscraps preparations, 19
- dermatofibrosarcoma protuberans, 38, 302
- desmoid-type fibromatosis, 302
- desmoplastic mesothelioma, 73
- desmoplastic small round cell tumor, 283
- diffuse large B-cell lymphoma, 262, 281
- diffuse large B-cell lymphoma with sclerosis, 85
- documentation of intraoperative activities, 9
- duodenal endocrine tumors, 124
- dysgerminoma, 225
- embryonal carcinoma, 87
- enchondroma, 313–14
- endocrine neoplasms
 - gastrointestinal tract, 123–6
 - multiple endocrine neoplasia, type 1 (MEN1), 148–50, 188
 - multiple endocrine neoplasia, types 2a and 2b, 188
 - pancreas, 148–50
- endoscopic mucosal resection (EMR), 121
- enteropathy-associated T-cell lymphoma, 262
- epidermolytic acanthoma, 38
- epithelial-myoepithelial carcinoma, 94, 95, 96, 104
- epithelioid hemangioendothelioma, 61
- epithelioid malignant mesothelioma, 73
- Epstein-Barr virus, 50
- esophageal carcinomas, 119–21
 - adenocarcinoma, 120–1
 - squamous cell carcinoma (SCC), 120
- evaluation of surgical margins, 2, 3–5
- Ewing sarcoma/peripheral primitive neuroectodermal tumors, 283
- excisional biopsy
 - lymph nodes, 255
 - soft tissue neoplasms, 289
- extrahepatic biliary atresia, 333–5
- extrahepatic biliary tract
 - distal lesions, 137–8
 - information needed before and during IOD, 130–1
 - lesions of the ampulla and periampullary region, 137–8
 - proximal lesions, 137
 - role of IOD in hepatobiliary disease, 130
- extramammary Paget’s disease, 37
- extranodal B-cell marginal zone lymphoma, 262
- extranodal lymphoma
 - general clinical issues, 262
 - intraoperative diagnosis, 262–4
 - specimen handling, 262–4
- extravasation mucocele, 102–3
- fallopian tube carcinoma, 233
- familial adenomatous polyposis, 121
- female genital tract
 - cervix, 232–3
 - changing role of the pathologist, 208
 - fallopian tubes, 233
 - lymph nodes, 233–4
 - ovary, 208–26
 - peritoneum, 235–7
 - uterus, 227–32
 - vagina, 235
 - vulva, 234–5
- fine needle aspiration (FNA) biopsy
 - lymph nodes, 254
 - soft tissue neoplasms, 289
 - thyroid nodules, 159
- fixation and staining of specimens, 20–2
- focal acantholytic dyskeratosis, 38
- focal nodular hyperplasia
 - liver, 134–5
- frozen section (FS) diagnosis
 - inappropriate requests for, 5
 - medical conditions of the skin, 39
 - unnecessary requests for, 5
- frozen section (FS) technique, 15–18
 - appropriate uses, 15
 - cryostats, 15
 - cutting sections, 17–18
 - freezing the block, 16–17
 - lifting the section onto the glass slide, 18
 - preparation of the frozen section block, 15–16
 - preparing and sampling the specimen, 15
- gallbladder carcinoma
 - clinical issues, 136
 - information needed before and during IOD, 130–1
 - pathologic issues, 136
 - role of IOD, 130
- ganglioglioma, 276
- gastric carcinoma, 122–3
- gastric endocrine tumors, 123–4
- gastric resection, 1
- gastrointestinal stromal tumors, 126–7
- gastrointestinal tract, 112–27
 - ampullary adenomas and adenocarcinomas, 121–2
 - appendiceal endocrine tumors, 125
 - appendiceal neoplasms, 114–17
 - colonic endocrine tumors, 125
 - colorectal carcinoma, 117–18
 - Crohn’s disease, 118–19
 - duodenal endocrine tumors, 124
 - endocrine tumors, 123–6
 - esophageal carcinomas, 119–21
 - gastric carcinoma, 122–3
 - gastric endocrine tumors, 123–4
 - gastroesophageal junction carcinomas, 119–21
 - gastrointestinal stromal tumors, 126–7
 - general clinical issues, 112
 - general pathologic issues, 113
 - goblet cell carcinoid, 125
 - Hirschsprung’s disease, 330–3
 - idiopathic chronic inflammatory bowel disease, 118–19
 - ileal endocrine tumors, 124–5
 - indications for intraoperative diagnosis, 112
 - information needed before and during IOD, 113–14
 - ischemic bowel disease, 119
 - jejunal endocrine tumors, 124–5
 - peri-ampullary adenomas and adenocarcinomas, 121–2
 - rectal carcinoid tumor, 125–6
 - ulcerative colitis, 118–19
- germ cell tumors, 225, 286
- germ cell tumors of the mediastinum, 85–7
 - choriocarcinoma, 87
 - classification, 86
 - clinical issues, 85–6

INDEX

- germ cell tumors of the mediastinum, (cont.)
 - embryonal carcinoma, 87
 - pathologic issues, 86–7
 - seminomas, 86–7
 - teratomas, 86
 - yolk sac tumor, 87
- giant cell rich osteosarcoma, 309–11
- giant cell tumor, 309–11
- glioblastoma, 273
- “go ahead rule”, 258
 - intraoperative staging of malignancies, 2
- goblet cell carcinoid, 125
- “good enough” diagnosis, 7
- granulomatous inflammation, 89
- Graves’ disease, 159
- gross examination of specimens, 13–15
 - as the only test, 13
 - in combination with other tests, 13–14
 - proper handling of specimens, 14–15
- hamartomatous lesions, 89
- Hashimoto’s disease, 159, 173–5
- head. *see* upper aerodigestive tract
- hematoxylin and eosin (H&E) stain, 20
- hepatic adenoma, 134–5
- hepatocellular carcinoma, 131–2, 134–5
- hepatosplenic T-cell lymphoma, 261
- hilar cholangiocarcinoma, 137
- Hirschsprung’s disease, 330–3
- Hodgkin’s lymphoma, 6, 84–5
- hybrid carcinomas, 47
- idiopathic chronic inflammatory bowel disease, 118–19
- idiopathic sclerosing mediastinitis, 89
- ileal endocrine tumors, 124–5
- imiquimod, 24
- immature teratoma, 225
- incisional biopsy
 - lymph nodes, 254
 - soft tissue neoplasms, 289
- infectious diseases, 18
- inflammatory bowel disease, 118–19
- inking of skin specimens, 25
- inking of surgical specimens, 3
- intradermal nevi, 38
- intrahepatic cholangiocarcinoma, 131–2, 133
- intramuscular myxoma, 296
- intraoperative consultation (IOC)
 - changing role of the pathologist, 1
 - communication between pathologist and surgeon, 8
 - definition of the pathologist’s role, 1
 - Quality Control and Quality Assurance, 10–11
- intraoperative diagnosis (IOD)
 - accuracy rates, 9–10
 - communication between pathologist and surgeon, 5–6
 - concept of a “good enough” diagnosis, 7
 - differences in use of, 1
 - documentation of intraoperative activities, 9
 - importance of clinico-pathologic correlation, 5–6
 - inappropriate requests for FS diagnosis, 5
 - medico-legal issues, 11
 - Quality Control and Quality Assurance, 10–11
 - telepathology, 11
 - turn-around time (TAT) for diagnoses, 8–9
 - unnecessary requests for FS diagnosis, 5
- intraoperative diagnosis (IOD) indications, 2–3
 - determine adequacy of incisional biopsy specimen, 2
 - diagnosis which will influence the surgical procedure, 2
 - evaluation of surgical margins, 2, 3–5
 - staging of malignant neoplasms, 2
 - to obtain fresh tissue for ancillary studies, 3
- intraoperative diagnosis (IOD) limitations, 6–7
 - FS sampling errors, 6
 - lesions not amenable to IOD, 6
 - non-representative incisional biopsy, 6
 - requirement for ancillary studies, 7
- intraoperative staging of malignancies
 - “go ahead rule”, 2
 - “stopping rule”, 2
- intravascular large B-cell lymphoma, 262
- ischemic bowel disease, 119
- ischemic fasciitis, 293–4
- islet cell tumors, 148
- jejunal endocrine tumors, 124–5
- joints. *see* bone and joint lesions
- juvenile granulosa cell tumor, 226
- juxtaoral organ of Cheivitz, 55
- keratoacanthoma, 32
- kidney, 244–8
 - evaluation of nephrectomy specimens with urothelial carcinoma, 246–7
 - evaluation of radical nephrectomy specimens, 245–6
 - frozen section to evaluate a cystic renal mass, 247
 - general clinical issues, 244
 - indications for intraoperative diagnosis, 244–5
 - partial nephrectomy specimens, 247–8
 - renal neoplasms of childhood, 326–8
- Klatskin tumor, 137
- Kuttner tumor, 104
- leiomyosarcoma, 38, 73, 299–300
- lentigo maligna, 36–7
- lipomatous neoplasms in soft tissue, 30–1
- liver
 - bile duct adenoma, 134
 - bile duct hamartoma, 133
 - evaluation of surgical margins in partial hepatectomy specimens, 131–3
 - focal nodular hyperplasia, 134–5
 - handling partial hepatectomy specimens, 132–3
 - hepatic adenoma, 134–5
 - hepatic tumors of childhood, 329–30
 - hepatocellular carcinoma, 134–5
 - indications for intraoperative diagnosis, 131
 - information needed before and during IOD, 130–1
 - intraoperative diagnosis of hepatic lesions, 133–5
 - lesions with ductal/glandular differentiation, 133–4
 - lesions with hepatocellular differentiation, 134–5
 - macrodegenerative nodule of cirrhosis, 134–5
 - metastatic adenocarcinoma, 134
 - partial hepatectomy for benign lesions, 131
 - partial hepatectomy for metastatic colon cancer, 132
 - partial hepatectomy for primary carcinomas of the liver, 131–2
 - partial hepatectomy in patients with cirrhosis, 132
 - role of IOD in hepatobiliary disease, 130
- liver transplantation
 - evaluation of a potential donor liver, 135
- low-grade fibromyxoid sarcoma, 295
- low-grade myxofibrosarcoma, 296
- lung
 - accuracy of intraoperative diagnosis, 74
 - pathologist’s role in disease management, 59
- lung (mass lesions)
 - apical cap lesions, 63
 - atypical adenomatous hyperplasia, 63
 - benign lesions that mimic bronchioalveolar carcinoma, 63–4
 - bronchioalveolar carcinoma, 62
 - carcinomas that resemble bronchioalveolar carcinoma, 65–7
 - classification of non-small cell carcinomas, 62
 - evaluation of lobectomy and pneumonectomy specimens, 68–9
 - handling specimens for a solitary nodule, 60–1
 - indications for intraoperative diagnosis (IOD), 59
 - information needed before and during IOC, 60
 - invasive adenocarcinoma, 62, 65–7
 - limited (wedge) resection of pulmonary neoplasms, 62–3
 - neuroendocrine neoplasms, 69–70
 - papillary adenocarcinoma, 65
 - papillary adenoma, 64
 - primary versus metastatic carcinoma in wedge biopsy, 61–2
 - resection of metastatic malignancies, 70
 - scar-associated reactive changes, 63
 - solitary pulmonary lesion, 60–1, 61–2
 - staging of lung carcinoma, 67–8
 - wedge biopsy and wedge resection specimens, 60–1
 - wedge resection of pulmonary neoplasms, 62–3
- lung (pleural based lesions), 73–5
 - clinical issues, 73
 - pathologic issues, 73–4
- lung disease (diffuse or infiltrative)
 - clinical issues, 71–2
 - determining specimen adequacy, 72
 - familiarity with the surgeon’s operative plan, 72
 - indications for IOD, 70
 - inflating the specimen, 72
 - information needed before and during IOD, 70–2

INDEX

- pathologic issues, 72–3
- procuring tissue for culture, 72
- lymph nodes
 - B-cell and T-cell rearrangement studies, 257
 - clinical issues, 254
 - cytogenetic studies, 257
 - cytologic examination, 255
 - evaluation during cystectomy, 244
 - evaluation during penectomy, 252
 - excisional biopsy, 255
 - female genital tract, 233–4
 - fine needle aspiration (FNA) biopsy, 254
 - frozen section examination, 255
 - gross examination, 255
 - immunophenotyping by flow cytometry, 256–7
 - incisional biopsy, 254
 - indications for intraoperative diagnosis, 259
 - information needed before and during IOD, 257–8
 - IOD techniques, 255
 - microbiologic cultures, 257
 - needle core biopsy, 254
 - proper handling of specimens, 255
 - reporting the results of IOD, 260–1
 - sampling for ancillary studies, 256–7
 - sentinel lymph node biopsy, 258–9
- lymphadenoma, 105
- lymphoblastic lymphoma, 85
- lymphoepithelial carcinoma, 106
- lymphoepithelial sialadenitis (LESA), 104
- lymphoepithelioma, 50
- lymphoid lesions
 - salivary glands, 104
- lymphoid neoplasms
 - squash and smear preparations, 19
- lymphomas, 84–5
 - central nervous system, 273
 - clinical issues, 84
 - diffuse large B-cell lymphoma with sclerosis, 85
 - Hodgkin's lymphoma, 6, 84–5
 - lymphoblastic lymphoma, 85
 - non-Hodgkin's lymphoma, 84, 262
 - pathologic issues, 84–5
 - thyroid gland, 175–6
 - See also extranodal lymphoma.
- lymphoplasmacytic sclerosing pancreatitis, 147
- lymphoproliferative lesions
 - central nervous system, 281–2
- M.D. Anderson Hospital, 15, 17
- male genital system
 - penis, 251–2
 - prostate, 248–50
 - testis, 250–1
- malignant spiradenoma, 34
- MALT lymphoma, 262
- MALTomas, 104
- mantle cell lymphoma, 262
- massive localized lymphedema, 294
- Mayo Clinic, 1, 15, 17
- mediastinum, 77–90
 - benign lesions, 89–90
 - general clinical issues, 77
 - general pathologic issues, 78–9
 - germ cell tumors, 85–7
 - indications for intraoperative consultation, 77
 - information needed before and during surgery, 78
 - lymphomas, 84–5
 - mesenchymal tumors, 87–9
 - neuroendocrine carcinomas of the thymus, 83–4
 - thymomas, 79–83
 - medico-legal issues, 11
 - medulloblastoma, 283
 - melanocytic neoplasms, 36–7
 - melanoma, 36–7, 73
 - meningiomas, 278–80
 - Merkel cell carcinoma, 34–5
 - mesenchymal neoplasms, 38
 - mesenchymal tumors of the mediastinum, 87–9
 - clinical issues, 87
 - neural neoplasms, 89
 - pathologic issues, 88–9
 - solitary fibrous tumor, 88
 - synovial sarcoma, 88–9
 - metastases
 - central nervous system, 273, 280–1
 - resection of pulmonary metastases, 70
 - salivary glands, 108–9
 - thyroid gland, 173
 - metastatic adenocarcinoma, 133
 - liver, 134
 - metastatic colon cancer
 - partial hepatectomy, 132
 - microcystic adnexal carcinoma, 34
 - Mohs micrographic surgery, 5, 24, 28–9, 30, 32, 33, 36, 37, 38
 - special stains, 22
 - monophasic synovial sarcoma, 296
 - mouth. *see* salivary glands, upper aerodigestive tract
 - mucicarmine stain, 21
 - mucinositis peritonei, 215, 221
 - mucinous adenocarcinoma, 34
 - mucoepidermoid carcinoma, 94, 102–3, 104, 106
 - multiple endocrine neoplasia
 - type 1 (MEN1), 148–50, 188
 - type 2a (MEN2a), 188
 - type 2b (MEN2b), 188
 - myofibroblastic inflammatory pseudotumor, 89
 - myxoid liposarcoma, 296
 - myxoid neoplasms in soft tissue, 297
- nasal-type extranodal NK/T-cell lymphoma, 262
- nasopharyngeal carcinoma, 50
- necrotizing sialometaplasia, 53
- needle core biopsy
 - lymph nodes, 254
 - soft tissue neoplasms, 289
- neural neoplasms of the mediastinum, 89
- neuroendocrine carcinomas of the thymus, 83–4
- nodular fasciitis, 293
- non-Hodgkin's lymphoma, 84, 262
- odontogenic rests, 53–5
- oligodendrogliomas, 274–5
- orientation of skin specimens, 25
- orientation of surgical specimens, 3
- osteomyelitis, 318–19
- osteosarcoma, 314–17
- ovary, 208–26
 - Brenner tumor, 217
 - carcinoid tumor, 217
 - clear cell carcinoma, 215–16
 - endometrioid carcinoma, 216–18
 - evaluating high-grade malignancies, 18
 - general clinical issues, 208
 - general pathologic issues, 208–10
 - hemorrhagic ovarian cyst, 226
 - indications for intraoperative consultation, 208
 - lesions in the pediatric and postpubertal patient, 224–6
 - lesions related to pregnancy, 223–4
 - metastases to the ovary, 218–23
 - metastatic colon cancer, 218
 - mucinous tumors, intestinal type, 213–15
 - serous tumors, 210–13
 - sex cord-stromal tumor, 217, 223, 225
 - undifferentiated malignant neoplasms, 218
- Paget's disease, 37
- pancreas, 140–58
 - acinar carcinoma, 147–8
 - algorithmic approach to diagnosis of pancreatic lesions, 141–3
 - approach to intraoperative consultation, 140
 - cystic neoplasms, 151–8
 - indications for intraoperative consultation, 140
 - information needed before and during IOC, 140–1
 - intraductal papillary mucinous neoplasms, 155–8
 - lymphoplasmacytic sclerosing pancreatitis, 147
 - mucinous cystic neoplasms, 154–5
 - multiple endocrine neoplasia, type 1 (MEN1), 148–50
 - pancreatic adenocarcinoma, 143–7
 - pancreatic endocrine neoplasms, 148–50
 - pancreatoblastoma, 150
 - serous cystic neoplasms, 152–4
 - solid-pseudopapillary neoplasms, 150–1
 - pancreatic adenocarcinoma, 143–7
 - pancreatitis, 143, 144
 - pancreatoblastoma, 150
 - papillary digital eccrine adenocarcinoma, 34
 - papillary keratosis, 46
 - parathyroid gland, 179–89
 - anatomic location of abnormal parathyroid glands, 183
 - atypical adenoma, 187
 - carcinomas, 188–9
 - causes of primary hyperparathyroidism, 179
 - familial primary hyperparathyroidism, 180, 188
 - hamartoma, 187
 - handling specimens intraoperatively, 181–2
 - hyperparathyroidism-jaw tumor syndrome, 188
 - information needed before and during IOC, 181
 - isolated familial hyperparathyroidism, 188

INDEX

- parathyroid gland, (cont.)
 - lipoadenoma, 187
 - management of hyperparathyroidism, 179
 - MEN type 1, 187
 - MEN types 2a and 2b, 188
 - normal parathyroid gland, 183
 - parathyroid adenoma, 183–7
 - parathyromatosis, 189
 - persistent hyperparathyroidism, 180–1
 - recurrent hyperparathyroidism, 180–1
 - secondary hyperparathyroidism, 189
 - sporadic primary hyperparathyroidism, 180
 - sporadic primary hyperplasia, 187–8
 - surgical approach to primary
 - hyperparathyroidism, 179–81
 - syndromic primary hyperparathyroidism, 180
 - tertiary hyperparathyroidism, 189
- parathyroid gland specimens
 - accurate labeling of specimens, 181
 - frozen section vs. cytologic preparations, 181
 - gross examination, 181
 - handling specimens intraoperatively, 181–2
 - inking the specimen, 181
- PAS-diastase stain, 21
- pediatric surgical pathology, 322–35
 - differences between pediatric and adult patients, 322
 - evaluation of surgical margins, 326
 - extrahepatic biliary atresia, 333–5
 - hepatic tumors of childhood, 329–30
 - Hirschsprung’s disease, 330–3
 - indications for IOC, 323
 - information needed before and during IOC, 322–3
 - renal neoplasms of childhood, 326–8
 - resection specimens, 326
 - small round blue cell tumors
 - of childhood, 323–6
- penis, 251–2
 - evaluation of lymph nodes during penectomy, 252
 - evaluation of surgical margins in penectomy specimens, 251–2
 - indications for IOD, 251
 - squamous cell carcinoma, 251
- peptic ulcer disease, 1
- peri-ampullary adenomas and adenocarcinomas, 121–2
- peritoneum
 - female genital tract, 235–7
 - general pathologic issues, 236–7
 - indications for intraoperative diagnosis, 235
 - lesions related to pregnancy, 223–4
- photodynamic therapy for cutaneous malignancies, 24
- phylloides tumors, 200–1
- pilocytic astrocytoma, 276
- pilomyxoid astrocytoma, 277
- pineal neoplasms, 287
- pituitary adenomas, 286
- plasmablastic lymphoma, 262
- pleomorphic adenoma, 94
- pleomorphic xanthoastrocytoma, 276
- pleural based lesions, 73–5
- porocarcinoma, 34
- primary effusion lymphoma, 262
- primitive neuroectodermal tumors, 283
- progressive multifocal leukoencephalopathy, 272
- proliferative verrucous leukoplakia, 46
- prostate, 248–50
 - evaluation of pelvic lymph nodes during radical prostatectomy, 249–50
 - evaluation of surgical margins in prostate carcinoma, 249
 - indications for intraoperative diagnosis, 248
 - prostate cancer treatments, 248
- pseudoepitheliomatous hyperplasia, 32, 53
- pseudomyxoma peritonei, 215, 221
- pyloroplasty, 1
- Quality Assurance in IOC, 10–11
- Quality Control in IOD, 10
- radiation atypia in resected specimens, 51
- rectal carcinoid tumor, 125–6
- Richter’s transformation, 258
- salivary gland tumors, 92–111
 - carcinoma arising in pleomorphic adenoma, 100–1
 - changes secondary to FNA biopsy, 109
 - clear cell neoplasms, 104–5
 - cystic lesions, 102–3
 - epithelial tumors with a heavy lymphoid component, 105–6
 - fine needle aspiration (FNA) biopsy, 92
 - FS evaluation of the facial nerve, 109–11
 - general clinical issues, 92–3
 - general pathologic issues, 93–6
 - handling specimens for IOD, 97–8
 - indications for intraoperative diagnosis, 92
 - information needed before and during IOC, 97
 - lymphoid lesions, 104
 - metastatic malignancies, 108–9
 - multiple neoplasms in major salivary glands, 107–8
 - oncocytic neoplasms, 106
 - pleomorphic adenoma in minor salivary glands, 100
 - pleomorphic adenoma variants (benign mixed tumor), 98–100
- sarcomatoid carcinoma
 - upper aerodigestive tract, 49–50
- sarcomatoid mesothelioma, 73
- schwannomas with degenerative atypia, 295
- sclerosing sialadenitis (Kuttner tumor), 104
- scrape and smear preparations, 19
- sebaceous carcinoma, 33–4
- sebaceous cystadenoma, 102
- sebaceous lymphadenocarcinoma, 106
- sebaceous lymphadenoma, 105
- sellar lesions, 285–6
- seminomas, 86–7
- sentinel lymph node biopsy, 258–9
 - in SCC, 55–6
- sex cord-stromal tumor, 217, 223, 225
- signet ring cell carcinomas, 113
- skin
 - frozen sections for medical conditions, 39
 - staphylococcal scalded skin syndrome (SSS), 39
 - toxic epidermal necrolysis (TEN), 39
 - See also* cutaneous malignancies.
- small cell astrocytomas, 283
- small cell lymphomas (MALTomas), 104
- small round blue cell tumors
 - central nervous system, 283
 - of childhood, 323–6
- small round cell neoplasms of bone, 317
- smooth muscle neoplasms, 299–300
- soft tissue neoplasms, 288–303
 - atypical decubital fasciitis, 293–4
 - benign neoplasms that simulate malignancy, 294–5
 - biopsy procedures, 289
 - bland appearing malignancies, 295–6
 - cellular myofibroblastic lesions, 295
 - cellular schwannoma, 294–5
 - choice of surgical procedure, 288–9
 - diagnostic challenges, 288
 - evaluation of surgical margins in bland,
 - locally aggressive neoplasms, 302–3
 - evaluation of surgical margins in sarcomas, 301–2
 - excisional biopsy, 289
 - fine needle aspiration (FNA) biopsy, 289
 - general clinical issues, 288–90
 - general pathologic issues, 291
 - handling specimens intraoperatively, 292
 - incisional biopsy, 289
 - indications for intraoperative consultation (IOC), 290
 - information needed before and during IOC, 290–1
 - information required for IOD, 290–1
 - intramuscular myxoma, 296
 - ischemic fasciitis, 293–4
 - leiomyosarcoma, 299–300
 - low-grade and high-grade sarcoma, 296–7
 - low-grade fibromyxoid sarcoma, 295
 - low-grade myxofibrosarcoma, 296
 - management challenges, 288
 - managerial classification, 289
 - massive localized lymphedema, 294
 - monophasic synovial sarcoma, 296
 - myxoid liposarcoma, 296
 - myxoid neoplasms, 297
 - needle core biopsy, 289
 - neoplasms with a mature lipomatous component, 300–1
 - nodular fasciitis, 293
 - pre-treatment evaluation, 288–9
 - reactive lesions that simulate malignancy, 292–4
 - schwannomas with degenerative atypia, 295
 - smooth muscle neoplasms, 299–300
 - specific clinicopathologic issues, 292–303
 - spindle cell malignancy in superficial locations, 300
 - spindle cell neoplasms in parenchymal organs, 301
 - surgical procedures, 290
 - tumor heterogeneity, 296–7
- solid pseudopapillary neoplasms, 150–1
- solitary fibrous tumor, 88
 - of the pleura, 73
- spinal cord lesions, 283–4
- spindle cell carcinoma, 73
- spindle cell squamous carcinoma
 - upper aerodigestive tract, 49–50

INDEX

- spleen
 - general clinical issues, 261
 - hepatosplenic T-cell lymphoma, 261
 - intraoperative diagnosis, 261–2
 - specimen handling, 261–2
 - splenic B-cell marginal zone lymphoma, 261
- splenic B-cell marginal zone lymphoma, 261
- squamous cell carcinoma (SCC), 32–3
 - actinic keratoses, 33
 - clinical issues, 32
 - high-risk type, 32
 - infiltrative capacity, 32
 - low-risk type, 32
 - pathological issues, 32–3
 - perineural invasion, 32
 - risk of metastasis, 32
 - spindle cell squamous carcinoma, 33
 - verrucous carcinoma of the skin, 32
- squash and smear preparations (squash preparations), 19
 - in neuropathology, 268
- staining of specimens, 20–2
 - rapid stains, 21–2
 - special stains, 21–2
- staphylococcal scalded skin syndrome (SSS), 39
- stereotactic needle biopsy, 266, 272–3
- stomach
 - peptic ulcer disease, 1
- “stopping rule”, 258
 - intraoperative staging of malignancies, 2
- synovial sarcoma, 73, 88–9
- techniques used for IOD, 13–22
 - cytologic examination of specimens, 18–19
 - fixation and staining of specimens, 20–2
 - frozen section (FS) technique, 15–18
 - gross examination of specimens, 13–15
- telepathology, 11
- teratomas, 86
- testicular neoplasms, 250–1
 - diagnosis, 250
 - indications for IOD, 250–1
 - retroperitoneal lymph node dissection, 251
- thymic cysts, 89
- thymic hyperplasia, 89
- thymolipoma, 89
- thymomas, 79–83
 - clinical issues, 79
 - lymphocyte-rich thymomas, 80–1
 - pathologic issues, 79–83
 - spindle cell thymomas, 81–2
 - thymic carcinomas, 82–3
 - thymomas rich in epithelial cells, 82
- thymus
 - multilocular thymic cyst, 89
- neuroendocrine carcinomas, 83–4
- thyroid gland, 159–76
 - anaplastic carcinoma, 171–2
 - cystic papillary carcinoma, 167
 - diagnostic ultrasonography, 159
 - fine needle aspiration (FNA) biopsy, 159
 - follicular adenoma, 168–70
 - follicular neoplasms, 168–70
 - follicular variant of PTC, 165–6
 - general clinical issues, 159–60
 - handling lobectomy specimens, 160–1
 - handling specimens intraoperatively, 160–3
 - handling subtotal and total thyroidectomy specimens, 161
 - Hashimoto’s disease, 173–5
 - Hurthle cell neoplasms, 170
 - hyalinizing trabecular neoplasms, 171
 - indications for intraoperative consultation, 160
 - information needed before and during surgery, 160
 - lobectomy specimens, 13
 - lymphomas, 175–6
 - medullary carcinoma, 172–3
 - metastatic neoplasms, 173
 - minimally invasive follicular carcinoma, 168–70
 - multinodular goiter (MNG), 163
 - papillary lesions that mimic papillary carcinoma, 167
 - papillary microcarcinoma, 165
 - papillary thyroid carcinoma (PTC) and variants, 163–7
 - poorly differentiated thyroid carcinoma, 171
 - total thyroidectomy treatment, 159
 - use of frozen section intraoperatively, 159
 - widely invasive follicular carcinoma, 168–70
- Thyroid Transcription Factor 1 (TTF-1) stain, 61
- thyroiditis, 175
- toluidine blue stain, 21
- tonsillectomy specimens, 44–5
- topical immune modulators, 24
- touch imprints, 18
- touch preparations, 18
- toxic epidermal necrolysis (TEN), 39
- transitional cell carcinoma, 240
- turn-around time (TAT) for IOD, 8–9
- ulcerative colitis, 118–19
- ultrasonography
 - thyroid nodules, 159
- upper aerodigestive tract malignancies, 41–56
 - basaloid squamous cell carcinoma, 48
 - benign lesions that might be mistaken for, 53–4
 - biopsies, 41
 - carcinoma-in-situ at surgical margins, 50–2
 - carcinosarcoma, 49–50
 - cystic metastatic SCC in cervical lymph nodes, 55
 - diagnostic challenges, 41
 - distinguishing radiation-induced atypia, 51
 - dysplasia at surgical margins, 50–2
 - evaluation of bone margins, 52
 - evaluation of nerve margins, 52–3
 - general clinical issues, 41–2
 - grading of dysplasia, 50–2
 - impact of surgical margins in SCC, 45
 - incisional biopsy, 41
 - indications for IOD, 42
 - information needed before and during surgery, 42–3
 - information needed for IOD, 42–3
 - laser excision, 42
 - nasopharyngeal carcinoma, 50
 - normal structures that may be mistaken for, 53–5
 - pathologic characteristics of SCC, 45
 - radiation atypia in resected specimens, 53
 - sarcomatoid carcinoma, 49–50
 - sentinel lymph node biopsy in SCC, 55–6
 - spindle cell squamous carcinoma, 49–50
 - surgical resection, 42
 - variety of neoplasms, 41
 - verrucous squamous cell carcinoma, 46–7
 - See also salivary glands.*
- upper aerodigestive tract specimens
 - evaluation of margins, 43–5
 - handling of specimens, 43–5
 - large keratotic lesions, 44
 - reporting positive margins, 45
 - sampling the margins of resected specimens, 44
 - separate biopsies from the resection bed, 43
 - thickness of frozen sections for margins, 45
 - tonsillectomy specimens, 44–5
- urinary tract
 - diagnosis of bladder carcinoma, 240
 - evaluation of pelvic lymph nodes during cystectomy, 244
 - evaluation of surgical margins during cystoprostatectomy, 240–2
 - evaluation of surgical margins during partial cystectomy, 242–3
 - evaluation of surgical margins during radical cystectomy, 240–2
 - extravesical lesions, 243
 - indications for intraoperative diagnosis (IOD), 240
 - information needed before and during IOC, 240
 - initial diagnosis of bladder lesions, 243
 - kidney, 244–8
 - management of neoplasms, 240
 - role of intraoperative diagnosis (IOD), 240
 - serosal nodules of the bladder, 243
 - urothelial carcinoma, 240
- urothelial carcinoma, 240
- uterus, 227–32
 - evaluation for possible intrauterine pregnancy, 230–1
 - hysterectomy specimen in patients with endometrial carcinoma, 227–9
 - hysterectomy specimen with unusual uterine mass, 230
 - indications for intraoperative diagnosis, 227
 - massive uterine hemorrhage, 231–2
 - myomectomy, 229
 - suspected ectopic pregnancy, 230–1
 - unusual uterine mass, 229–30
- vaginal lesions, 235
- vagotomy, 1
- verruca vulgaris, 46
- verrucous carcinoma of the skin, 32
- verrucous hyperplasia, 47
- verrucous squamous cell carcinoma
 - upper aerodigestive tract, 46–7
- von Hippel Lindau syndrome, 152
- von Meyenburg complex, 133
- vulval lesions, 234–5
- Warthin’s tumor, 94, 102, 105, 106
- Whipple’s procedure, 121
- Wilms’ tumor, 326
- yolk sac tumor, 87, 225, 226